CytoSorbents Announces Rights Offering
09. Dezember 2024 07:00 ET
|
CytoSorbents
CytoSorbents Announces Rights Offering Exclusive to Stockholders Who Hold or Have Bought CTSO Common Stock by Market Close on Friday, December 13, 2024
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
26. November 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Participate in the Piper Sandler 36th Annual Healthcare Conference. Management holding one-on-one meetings with investors
Peripheral Arterial Disease (PAD) Pipeline Research Report 2024: Comprehensive Insights About 22+ Pipeline Drugs Featuring AdvanceCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa, IsomAb
21. November 2024 04:20 ET
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Peripheral Arterial Disease (PAD)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. "Peripheral Arterial...
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
22. Oktober 2024 07:00 ET
|
CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
01. Oktober 2024 07:00 ET
|
CytoSorbents
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
07. August 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Report Q2 2024 Financial and Operating Results
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
02. Mai 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
XARELTO Market Size, Forecast, and Market Insight to 2032, with Focus on the United States and Japan
04. April 2024 11:13 ET
|
Research and Markets
Dublin, April 04, 2024 (GLOBE NEWSWIRE) -- The "XARELTO Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.The report provides...
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
28. Dezember 2023 07:00 ET
|
CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
27. September 2023 07:00 ET
|
CytoSorbents
CytoSorbents summarizes real-world data from STAR Registry analysis being presented next week at European Association of Cardio-Thoracic Surgery Congress